Loading ...

Carol Soppe

Immune Tolerance Network

Associate Director, Clinical Operations

http://www.immunetolerance.org

Assessment Group

Type 1 Diabetes

csoppe@immunetolerance.org

Work:

415-353-4879

Mobile:

415-278-1706

Address:

Immune Tolerance Network

Committees:

,

Studies:

ITN007AI

-

Treatment With hOKT3gamma1(Ala-Ala) in T1DM

ITN012AI

-

Autoantigen Vaccination in Human Type 1 DM

ITN017AI

-

Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus

ITN018AI

-

Proleukin and Rapamune in Type 1 Diabetes

ITN027AI

-

Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

ITN028AI

-

Study of Antithymocyte Globulin for Treatment of New-onset T1DM

ITN041AI

-

A Research Trial of Aralast in New Onset Diabetes

ITN042AI

-

ITN044AI

-

ITN045AI

-

Inducing Remission in Type 1 Diabetes With Alefacept

ITN058AI

-

Tocilizumab (TCZ) in New-onset Type 1 Diabetes

ITN064AI

-

Imaging of Type 1 Diabetes Progression

ITN065AI

-

TCZ in Pediatric New-onset T1D

ITN066AI

-

Type 1 Diabetes Extension Study

ITN078AI

-

Immunotherapy to Preserve Residual Insulin in New-onset Type One Diabetes

ITN504AI

-

Cytokine Production in Diabetic and Pre-Diabetic Children

ITN508AI

-

T Cell Assay Assessment

ITN512AI

-

ITN513AI

-

POPPII-1-Preservation of Pancreatic Production of Insulin through Immunosuppression

ITN514AI

-

Rituximab (anti-CD20) in new-onset T1D

ITN515AI

-

ITN516AI

-

ITN517AI

-

ITN518AI

-

ITN521AI

-

New Onset Metabolic Control Protocol

ITN819AI

-

Type 1 Diabetes Immunotherapy Using Polyclonal Tregs

ITN825AI

-

Imatinib in New-onset T1D

ITN826AI

-

Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1D

ITN827AI

-

Tregs and IL-2 in Type 1 Diabetes

ITN829AI

-

ActoBio AG019 (L. lactis) and teplizumab

Bio:

Admin Links

Shortcuts

ITN Documents

Links